Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy

被引：1
|
作者：
McNamara, Blair [1 ]
Bellone, Stefania [1 ]
Demirkiran, Cem [1 ]
Hartwich, Tobias Max Philipp [1 ]
Santin, Alessandro D. [1 ,2 ]
机构：
[1] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA
[2] 333 Cedar St,LSOG 305,POB 208063, New Haven, CT 06520 USA
来源：
GYNECOLOGIC ONCOLOGY REPORTS | 2023年 / 48卷
关键词：
Lenvatinib; Pembrolizumab; Clear Cell Ovarian cancer; Recurrent; Treatment-resistant;
D O I：
10.1016/j.gore.2023.101218
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Background: Treatment of ovarian clear cell carcinoma (CCC) poses many challenges. Effective treatment options for recurrent and metastatic disease remain limited. Case: A 70-year-old woman with recurrent metastatic ovarian CCC experienced durable response to the com-bination of pembrolizumab, a PD-1 targeting monoclonal antibody and lenvatinib, an oral multikinase inhibitor, after failing standard and experimental treatments. She experienced a 40.1% reduction of target lesions over 26 weeks of therapy. CA-125 trends confirmed serial CT scan findings of shrinking disease burden. She experienced overall mild side effects from the drug combination, and lenvatinib dosage was decreased from 20 to 10 mg/day over her 10 cycles. Conclusion: The combination of pembrolizumab and lenvatinib may represent a new treatment option for chemotherapy-resistant ovarian CCC.
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Durable response and adverse events in a patient with non-MSI-H uterine clear cell carcinoma on pembrolizumab/ lenvatinib
    Chan, Jack Junjie
    Tan, Hui Zhuan
    ANNALS OF ONCOLOGY, 2023, 34 : S1464 - S1464
  • [22] Recurrent ovarian clear cell carcinoma: a retrospective evaluation of the efficacy and prognostic factors
    Song, Nan
    Yan, Xin
    Gao, Yunong
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (04) : 569 - 574
  • [23] Management and clinical outcomes of patients with recurrent/progressive ovarian clear cell carcinoma
    Huang, Huei-Jean
    Yang, Lan-Yan
    Tung, Hsiu-Jung
    Ku, Fei-Chun
    Wu, Ren-Chin
    Tang, Yun-Hsin
    Chang, Wei-Yang
    Jung, Shih-Ming
    Wang, Chun-Chieh
    Lin, Cheng-Tao
    Liu, Feng-Yuan
    Lin, Gigin
    Chen, Min-Yu
    Chou, Hung-Hsueh
    Chang, Ting-Chang
    Chao, Angel
    Lai, Chyong-Huey
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2020, 119 (04) : 793 - 804
  • [24] Is adjuvant chemotherapy beneficial for surgical stage I ovarian clear cell carcinoma
    Hogen, Liat
    Brar, Harry
    Covens, Allan
    Bassiouny, Dina
    Bernardini, Marcus Q.
    Gien, Lilian T.
    Ferguson, Sarah E.
    Vicus, Danielle
    GYNECOLOGIC ONCOLOGY, 2017, 147 (01) : 54 - 60
  • [25] Is Adjuvant Chemotherapy Beneficial For Surgical Stage I Ovarian Clear Cell Carcinoma?
    Hogen, L.
    Brar, H.
    Covens, A.
    Bassiouny, D.
    Bernardini, M.
    Gien, L.
    Rosen, B.
    Le, L.
    Vicus, D.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 717 - 717
  • [26] Synergistic clinical efficacy of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma
    Tymon-Rosario, Joan
    Zeybek, Burak
    Han, Chanhee
    Santin, Alessandro D.
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [27] Efficacy of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell carcinoma
    Volkova, M., I
    Kalpinskiy, A. S.
    Goncharova, O. A.
    Menshikov, K. V.
    Stativko, O. A.
    Karabina, E. V.
    Dergunov, A. S.
    Polshina, N. I.
    Aleksandrova, E. N.
    Lebedinets, A. A.
    Panov, A. K.
    Sultanbaev, A. V.
    Usynin, E. A.
    Volkonsky, M. V.
    Mikhalyuk, V. V.
    Zukov, R. A.
    Anzhiganova, Yu. V.
    Gusniev, M. A.
    Igumnova, E. N.
    Kuzmicheva, S. V.
    Pokataev, I. A.
    Olshanskaya, A. S.
    Pervakova, N. I.
    Parsadanova, E. L.
    Sannikova, T. A.
    Bystrov, A. A.
    Dubovichenko, D. M.
    Mukhitova, M. R.
    Chubenko, V. A.
    Shkret, K. A.
    Gorshenina, M. N.
    Semenov, A. V.
    Davlatova, M. K.
    Kosareva, A. E.
    Lutoshkina, O. A.
    Maslova, O. A.
    Makhnutina, M. V.
    Mishina, A. V.
    Murzalina, M. Zh.
    Podyacheva, O. A.
    Kalinin, S. A.
    Mailyan, O. A.
    Safarova, A. R.
    Semenova, K. O.
    Strokova, M. A.
    Urashkina, E. Yu.
    Shmygina, O. S.
    Novikova, O. Yu.
    ONKOUROLOGIYA, 2024, 20 (03):
  • [28] Lenvatinib plus pembrolizumab in patients with renal cell carcinoma: Updated results
    Lee, Chung-Han
    Makker, Vicky
    Rasco, Drew
    Taylor, Mathew
    Stepan, Daniel E.
    Shumaker, Robert
    Schmidt, Emmett V.
    Guo, Matthew
    Dutcus, Corina
    Young, Louise
    Motzer, Robert
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 174 - 175
  • [29] Squamous Cell Carcinoma Transformation as a Possible Resistant Mechanism Against Pembrolizumab Plus Chemotherapy
    Kozuma, Yuka
    Toyokawa, Gouji
    Shoji, Fumihiro
    Yamazaki, Koji
    Kawauchi, Shigeto
    Momosaki, Seiya
    Takeo, Sadanori
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : E238 - E240
  • [30] Re: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2021, 206 (06): : 1518 - 1519
12345